Skip to main content
Erschienen in: Hepatology International 4/2012

01.10.2012 | Original Article

A Novel prognostic scoring system to predict 3-month mortality risk in patients with acute-on-chronic liver failure in hepatitis B: a retrospective cohort study

verfasst von: Yu-Bao Zheng, Shi-Bin Xie, Dong-Ying Xie, Liang Peng, Zi-Ying Lei, Hong Deng, Bin-Liang Lin, Chao-Shuang Lin, Zhi-Xin Zhao, Wei-Min Ke, Zhi-Liang Gao

Erschienen in: Hepatology International | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The present study was done to establish an objective, sensitive prognostic scoring system and to determine the applicability of this model in predicting the 3-month mortality of patients with acute-on-chronic liver failure in hepatitis B (ACLFB).

Methods

We developed a novel prognostic scoring system, calculated from six clinical indices including serum total bilirubin, prothrombin activity, serum creatinine, hepatic encephalopathy, infections, and the depth of ascites from 499 patients with ACLFB. Differences in the sensitivity, specificity, and practicality of a Novel prognostic scoring system and the model of end-stage liver disease (MELD) were analyzed.

Results

The areas under the receiver operating characteristic curve (ROC) for the Novel scoring systems and MELD scoring systems were 0.967 (95% CI, 0.956–0.977) and 0.900 (95% CI, 0.878–0.922), respectively. The analysis of the ROC curve indicated that the Novel scoring systems were an exact, pertinent, and objective prognostic model with greater accuracy than the MELD. In the Novel scoring systems, the survival rate of these patients whose scores ranged from 2 to 6 was 98.80%, while for those whose scores point at 7 and 15, the mortality rates were 8.70% (2/23) and 95.45% (21/22), respectively, and the mortality rate of these patients whose scores were 16 and above was 100.00%. However, in the MELD prognostic scoring systems, there were no score ranges with 100.00% survival rate.

Conclusions

We developed an objective, pertinent, and sensitive prognostic scoring system that predicted the 3-month mortality of patients with ACLFB with greater accuracy than the MELD.
Literatur
1.
Zurück zum Zitat Chan AC, Fan ST, Lo CM, Liu CL, Chan SC, Ng KK, Yong BH, Chiu A, Lam BK. Liver transplantation for acute-on-chronic liver failure. Hepatol Int 2009;3:571–581PubMedCrossRef Chan AC, Fan ST, Lo CM, Liu CL, Chan SC, Ng KK, Yong BH, Chiu A, Lam BK. Liver transplantation for acute-on-chronic liver failure. Hepatol Int 2009;3:571–581PubMedCrossRef
2.
Zurück zum Zitat Cornberg M, Jaroszewicz J, Manns MP, Wedemeyer H. Treatment of chronic hepatitis B. Minerva Gastroenterol Dietol 2010;56:451–465PubMed Cornberg M, Jaroszewicz J, Manns MP, Wedemeyer H. Treatment of chronic hepatitis B. Minerva Gastroenterol Dietol 2010;56:451–465PubMed
3.
Zurück zum Zitat Wiersma ST, McMahon B, Pawlotsky JM, Thio CL, Thursz M, Lim SG, Ocama P, Esmat G, Maimuna M, Bell D, Vitoria M, Eramova I, Lavanchy D, Dusheiko G. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 28. 2010. doi:10.1111/j.1478-3231.2010.02373.x). Wiersma ST, McMahon B, Pawlotsky JM, Thio CL, Thursz M, Lim SG, Ocama P, Esmat G, Maimuna M, Bell D, Vitoria M, Eramova I, Lavanchy D, Dusheiko G. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 28. 2010. doi:10.​1111/​j.​1478-3231.​2010.​02373.​x).
4.
Zurück zum Zitat Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3:269–282PubMedCrossRef Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3:269–282PubMedCrossRef
5.
Zurück zum Zitat Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–470PubMedCrossRef Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–470PubMedCrossRef
6.
Zurück zum Zitat Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Devière J. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009;49:646–657PubMedCrossRef Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Devière J. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009;49:646–657PubMedCrossRef
7.
Zurück zum Zitat Lok AS, McMahon BJ. Chronic hepatitis B: AASLD practice guideline. Hepatology 2007;45:507–539PubMedCrossRef Lok AS, McMahon BJ. Chronic hepatitis B: AASLD practice guideline. Hepatology 2007;45:507–539PubMedCrossRef
8.
Zurück zum Zitat Novelli G, Rossi M, Ferretti G, Pugliese F, Ruberto F, Lai Q, Novelli S, Piemonte V, Turchetti L, Morabito V, Annesini MC, Berloco PB. Predictive criteria for the outcome of patients with acute liver failure treated with the albumin dialysis molecular adsorbent recirculating system. Ther Apher Dial 2009;13:404–412PubMedCrossRef Novelli G, Rossi M, Ferretti G, Pugliese F, Ruberto F, Lai Q, Novelli S, Piemonte V, Turchetti L, Morabito V, Annesini MC, Berloco PB. Predictive criteria for the outcome of patients with acute liver failure treated with the albumin dialysis molecular adsorbent recirculating system. Ther Apher Dial 2009;13:404–412PubMedCrossRef
9.
Zurück zum Zitat Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, Lok AS. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007;13:374–381PubMedCrossRef Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, Lok AS. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007;13:374–381PubMedCrossRef
10.
Zurück zum Zitat Avolio AW, Nure E, Pompili M, Barbarino R, Basso M, Caccamo L, Magalini S, Agnes S, Castagneto M. Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc 2008;40:1961–1964PubMedCrossRef Avolio AW, Nure E, Pompili M, Barbarino R, Basso M, Caccamo L, Magalini S, Agnes S, Castagneto M. Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc 2008;40:1961–1964PubMedCrossRef
11.
Zurück zum Zitat Bronsther O, Ersoz S, Tugcu M, Eghtesad B, Gurakar A, Van Thiel DH. Liver transplantation for HBV related disease under immunosuppression with tacrolimus: an experience with 78 consecutive cases. J Okla State Med Assoc 1995;88:103–108PubMed Bronsther O, Ersoz S, Tugcu M, Eghtesad B, Gurakar A, Van Thiel DH. Liver transplantation for HBV related disease under immunosuppression with tacrolimus: an experience with 78 consecutive cases. J Okla State Med Assoc 1995;88:103–108PubMed
12.
Zurück zum Zitat Samuel D. Liver transplantation for chronic hepatitis B. Gastroenterol Clin Biol 2008;32:S25–S33PubMedCrossRef Samuel D. Liver transplantation for chronic hepatitis B. Gastroenterol Clin Biol 2008;32:S25–S33PubMedCrossRef
13.
Zurück zum Zitat Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transplant 2010;16:300–307 Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transplant 2010;16:300–307
14.
Zurück zum Zitat O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439–445PubMed O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439–445PubMed
15.
Zurück zum Zitat Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, Blei AT, Fontana RJ, McGuire BM, Rossaro L, Smith AD, Lee WM. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007;35:2498–2508PubMedCrossRef Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, Blei AT, Fontana RJ, McGuire BM, Rossaro L, Smith AD, Lee WM. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007;35:2498–2508PubMedCrossRef
16.
Zurück zum Zitat Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864–871PubMedCrossRef Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864–871PubMedCrossRef
17.
Zurück zum Zitat Ishigami M, Honda T, Okumura A, Ishikawa T, Kobayashi M, Katano Y, Fujimoto Y, Kiuchi T, Goto H. Use of the model for end-stage liver disease (MELD) score to predict 1-year survival of Japanese patients with cirrhosis and to determine who will benefit from living donor liver transplantation. J Gastroenterol 2008;43:363–368PubMedCrossRef Ishigami M, Honda T, Okumura A, Ishikawa T, Kobayashi M, Katano Y, Fujimoto Y, Kiuchi T, Goto H. Use of the model for end-stage liver disease (MELD) score to predict 1-year survival of Japanese patients with cirrhosis and to determine who will benefit from living donor liver transplantation. J Gastroenterol 2008;43:363–368PubMedCrossRef
18.
Zurück zum Zitat Adam R, Lucidi V, Karam V. Liver transplantation in Europe: is there a room for improvement? J Hepatol 2005;42:33–40PubMedCrossRef Adam R, Lucidi V, Karam V. Liver transplantation in Europe: is there a room for improvement? J Hepatol 2005;42:33–40PubMedCrossRef
19.
Zurück zum Zitat Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King’s criteria. J Hepatol 1997;26:62–68PubMedCrossRef Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King’s criteria. J Hepatol 1997;26:62–68PubMedCrossRef
20.
Zurück zum Zitat Ke WM, Li XJ, Yu LN, Lai J, Li XH, Gao ZL, Chen PJ. Etiological investigation of fatal liver failure during the course of chronic hepatitis B in southeast China. J Gastroenterol 2006;41:347–351PubMedCrossRef Ke WM, Li XJ, Yu LN, Lai J, Li XH, Gao ZL, Chen PJ. Etiological investigation of fatal liver failure during the course of chronic hepatitis B in southeast China. J Gastroenterol 2006;41:347–351PubMedCrossRef
21.
Zurück zum Zitat Takahashi Y, Kumada H, Shimizu M, Tanikawa K, Kumashiro R. A multicenter study on the prognosis of fulminant viral hepatitis: early prediction for liver transplantation. Hepatology 1994;19:1065–1071PubMedCrossRef Takahashi Y, Kumada H, Shimizu M, Tanikawa K, Kumashiro R. A multicenter study on the prognosis of fulminant viral hepatitis: early prediction for liver transplantation. Hepatology 1994;19:1065–1071PubMedCrossRef
22.
Zurück zum Zitat Caraceni P, Santi L, Mirici F, Montanari G, Bernardi M. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. Dig Liver Dis 2011;43:242–245PubMedCrossRef Caraceni P, Santi L, Mirici F, Montanari G, Bernardi M. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. Dig Liver Dis 2011;43:242–245PubMedCrossRef
23.
Zurück zum Zitat Traeger T, Mikulcak M, Eipel C, Abshagen K, Diedrich S, Heidecke CD, Maier S, Vollmar B. Kupffer cell depletion reduces hepatic inflammation and apoptosis but decreases survival in abdominal sepsis. Eur J Gastroenterol Hepatol 2010;22:1039–1049PubMedCrossRef Traeger T, Mikulcak M, Eipel C, Abshagen K, Diedrich S, Heidecke CD, Maier S, Vollmar B. Kupffer cell depletion reduces hepatic inflammation and apoptosis but decreases survival in abdominal sepsis. Eur J Gastroenterol Hepatol 2010;22:1039–1049PubMedCrossRef
24.
Zurück zum Zitat Soga K, Tomikashi K, Miyawaki K, Fukumoto K, Wakabayashi N, Konishi H, Mitsufuji S, Yoshida N, Kokura S, Naito Y, Kataoka K, Yoshikawa T. MELD score, child-pugh score, and decreased albumin as risk factors for gastric variceal bleeding. Hepatogastroenterology 2009;56:1552–1556PubMed Soga K, Tomikashi K, Miyawaki K, Fukumoto K, Wakabayashi N, Konishi H, Mitsufuji S, Yoshida N, Kokura S, Naito Y, Kataoka K, Yoshikawa T. MELD score, child-pugh score, and decreased albumin as risk factors for gastric variceal bleeding. Hepatogastroenterology 2009;56:1552–1556PubMed
25.
Zurück zum Zitat Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, Chen YP. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol 2011;9:351–356PubMedCrossRef Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, Chen YP. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol 2011;9:351–356PubMedCrossRef
26.
Zurück zum Zitat Sun QF, Ding JG, Xu DZ, Chen YP, Hong L, Ye ZY, Zheng MH, Fu RQ, Wu JG, Du QW, Chen W, Wang XF, Sheng JF. Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. J Viral Hepat 2009;16:464–470PubMedCrossRef Sun QF, Ding JG, Xu DZ, Chen YP, Hong L, Ye ZY, Zheng MH, Fu RQ, Wu JG, Du QW, Chen W, Wang XF, Sheng JF. Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. J Viral Hepat 2009;16:464–470PubMedCrossRef
27.
Zurück zum Zitat Sun QF, Lu Y, Xu D, Lan XY, Liu JY, Sun XJ. The impact of HBeAg positivity/negativity and HBV DNA loads on the prognosis of chronic severe hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2006;14:410–413 [Article in Chinese].PubMed Sun QF, Lu Y, Xu D, Lan XY, Liu JY, Sun XJ. The impact of HBeAg positivity/negativity and HBV DNA loads on the prognosis of chronic severe hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2006;14:410–413 [Article in Chinese].PubMed
28.
Zurück zum Zitat Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011;53:774–780PubMedCrossRef Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011;53:774–780PubMedCrossRef
Metadaten
Titel
A Novel prognostic scoring system to predict 3-month mortality risk in patients with acute-on-chronic liver failure in hepatitis B: a retrospective cohort study
verfasst von
Yu-Bao Zheng
Shi-Bin Xie
Dong-Ying Xie
Liang Peng
Zi-Ying Lei
Hong Deng
Bin-Liang Lin
Chao-Shuang Lin
Zhi-Xin Zhao
Wei-Min Ke
Zhi-Liang Gao
Publikationsdatum
01.10.2012
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 4/2012
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-011-9335-2

Weitere Artikel der Ausgabe 4/2012

Hepatology International 4/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.